Revolution Medicines Begins Phase 3 Trial of Rasonque Combination in Pancreatic Cancer
MT newswire2026/10/05 13:4809:48 AM EDT, 10/05/2026 (MT Newswires) -- Revolution Medicines (RVMD) said Monday it has started treating patients in a phase 3 trial of Rasonque, or daraxonrasib, plus investigational zoldonrasib in adults with metastatic RAS G12D pancreatic cancer. The trial is evaluating the combination against gemcitabine and nab-paclitaxel as a first-line treatment, the company said. Dual primary endpoints are progression-free survival and overall survival, Revolution Medicines said. Price: 207.74, Change: +1.10, Percent Change: +0.53
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
About 700,000 BTC have flowed out of exchanges in the past year.
Korean retail investors shift to the US in Q3: Sold over 5.5 trillion won of Korean stocks, purchased more than 10 trillion won of US stocks
In the third quarter, Korean retail investors made net purchases of US stocks worth approximately 10.15 trillion won, marking a complete reversal from the previous pattern in the first half of the year, when they made net purchases of nearly 100 trillion won in KOSPI stocks. In September alone, the sell-off amount reached as high as 14.2 trillion won. Analysts attribute this shift to a combination of factors: a sharp decline in KOSPI at high levels, the continued strength of the US stock market driven by AI themes, and the appreciation of the Korean won reducing currency exchange costs.
Copper prices approach historic highs! UBS remains bullish: "Still most optimistic"
Crypto prices
More
